Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK961081

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Over the last decade, there has been a steady increase in the use of fixed dose combinations for the treatment of a range of… Expand
2016
2016
To investigate the pharmacokinetics of inhaled batefenterol (BAT) and fluticasone furoate (FF) given alone or in combination via… Expand
2015
2015
Through application of our multivalent approach to drug discovery we previously reported the first discovery of dual pharmacology… Expand
2015
2015
AbstractGSK961081 (batefenterol) is a novel bifunctional molecule composed of a muscarinic antagonist and a β2‐agonist. The aims… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2014
2014
To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given alone… Expand
2014
2014
PurposeThe objective of this study was to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2013
2013
GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and &bgr;-agonist activities. This was a 4-week… Expand
2013
2013
GSK961081 is an inhaled bi-functional molecule with both muscarinic antagonism and β2-agonism (MABA) properties. This randomised… Expand
2013
2013
BACKGROUND There are few data on the bronchodilatory effects of adding short-acting bronchodilators (SABA) to maintenance, long… Expand
2011
2011
Introduction: GSK961081 is a dual pharmacophore with both muscarinic antagonist and beta 2 agonist (MABA) activity. Objective: To… Expand